ProCE Banner Activity

CE / CME

Contemporary HIV Treatment and Prevention 2022: Integrating New Data From CROI 2022

Multimedia

Hear from expert faculty members as they present some of the most clinically relevant new data presented at CROI 2022 and discuss how they will incorporate the data on prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure strategies into their own practices.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Nurses: 1.25 Nursing contact hours

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: June 17, 2022

Expiration: June 16, 2023

No longer available for credit.

Share

Faculty

Joseph J. Eron Jr.

Joseph J. Eron Jr., MD

Herman and Louise Smith Distinguished Professor of Medicine
Chief, Division of Infectious Diseases
UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina

Jeffrey Kwong

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN

Professor, Division of Advanced Nursing Practice
Rutgers, The State University of New Jersey
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York

Milena Murray

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Gregory Huhn

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, IL

Daniel R. Kuritzkes

Daniel R. Kuritzkes, MD

Chief
Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Jointly provided by the Association of Nurses in AIDS Care and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply a thorough understanding of available clinical data, practice guidelines, and patient preferences to ensure that long-acting ART is considered as a treatment strategy for patients for whom it may be appropriate
  • Integrate strategies to administer long-acting ART, support patient adherence to dosing visits, and monitor its efficacy and safety in clinical settings
  • Appraise the role of long-acting PrEP in HIV prevention strategies based on considerations including efficacy, safety, and patient preferences

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Joseph J. Eron Jr., MD

Herman and Louise Smith Distinguished Professor of Medicine
Chief, Division of Infectious Diseases
UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV; researcher: Gilead Sciences, ViiV.

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN

Professor, Division of Advanced Nursing Practice
Rutgers, The State University of New Jersey
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York

Jeffrey Kwong, DNP, MPH, FAANP, FAAN, has no relevant conflicts of interest to report.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, has disclosed that she has received consultant/advisor/speaker fees from Gilead Sciences, Janssen, Merck, Theratechnologies, and ViiV Healthcare.

Faculty Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, IL

Gregory Huhn, MD, MPHTM, has disclosed that he has received consultant/advisor/speaker fees from Gilead Sciences, Integritas, Janssen, and ViiV Healthcare and funds for research support from Lilly.

Daniel R. Kuritzkes, MD

Chief
Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consultant/advisor/speaker fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi O. Taiwo, MBBS, has disclosed that he has received consulting fees from GlaxoSmithKline, Merck, and ViiV Healthcare.

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams, PharmD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-156-H02-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 17, 2022, through June 16, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ competence in implementing optimal HIV treatment and prevention strategies through the appropriate use of contemporary ARV regimens.